[Skip to Content]
[Skip to Content Landing]
Article
November 1993

Molecular Mechanisms of Resistance to Tamoxifen Therapy in Breast Cancer

Author Affiliations

From the Department of Surgery, University of Chicago (Ill) (Dr Morrow), and the Departments of Human Oncology and Pharmacology, University of Wisconsin, Madison (Dr Jordan). Dr Morrow is now with the Department of Surgery, Northwestern University, Chicago.

Arch Surg. 1993;128(11):1187-1191. doi:10.1001/archsurg.1993.01420230015002
Abstract

Clinical data suggest that the use of adjuvant tamoxifen citrate (Nolvadex) for a minimum of 5 years, and possibly indefinitely, will result in maximal antitumor benefit. There is concern that long-term tamoxifen maintenance therapy may result in the induction of drug resistance. This article reviews the potential molecular mechanisms of resistance to tamoxifen and explores the possibility of tamoxifen-stimulated tumor growth.

(Arch Surg. 1993;128:1187-1191)

×